Inhaled Dual PDE3/4 Inhibitor Ensifentrine for Chronic Obstructive Pulmonary Disease: A Potential Therapeutic Perspective

被引：2
|
作者：
Gan, Qiming [1 ]
Wu, Yanjuan [1 ]
Su, Xiaofen [1 ]
Wang, Jingcun [1 ]
Zhang, Haojie [1 ]
Zhang, Nuofu [1 ]
Wu, Kang [1 ]
机构：
[1] Guangzhou Med Univ, Guangzhou Inst Resp Hlth, Natl Ctr Resp Dis, Natl Clin Res Ctr Resp Dis,Affiliated Hosp 1,Stat, Guangzhou, Peoples R China
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2024年 / 209卷 / 02期
基金：
中国国家自然科学基金;
关键词：
D O I：
10.1164/rccm.202307-1143LE
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：223 / 224
页数：3
相关论文
共 50 条
  • [31] PRKCD as a potential therapeutic target for chronic obstructive pulmonary disease
    Li, Siqi
    Huang, Qiong
    Zhou, Dongbo
    He, Baimei
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2022, 113
  • [32] Direct Inhibitory Effect of the PDE4 Inhibitor Roflumilast on Neutrophil Migration in Chronic Obstructive Pulmonary Disease
    Dunne, Amy E.
    Kawamatawong, Theerasuk
    Fenwick, Peter S.
    Davies, Ceri M.
    Tullett, Hannah
    Barnes, Peter J.
    Donnelly, Louise E.
    AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2019, 60 (04) : 445 - 453
  • [33] Cachexia in chronic obstructive pulmonary disease: new insights and therapeutic perspective
    Sanders, Karin J. C.
    Kneppers, Anita E. M.
    van de Bool, Coby
    Langen, Ramon C. J.
    Schols, Annemie M. W. J.
    JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2016, 7 (01): : 5 - 22
  • [34] PDE4: A Novel Target in the Treatment of Chronic Obstructive Pulmonary Disease
    Michalski, J. M.
    Golden, G.
    Ikari, J.
    Rennard, S. I.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 (01) : 134 - 142
  • [35] Therapeutic potential of natural compounds for treatment of chronic obstructive pulmonary disease: Current status and future perspective
    Sahu, Sanjeev Kumar
    Rain, Musarraf
    Vyas, Manish
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY REPORTS, 2024, 11
  • [36] Low Oral Bioavailability of RPL554, a First-in-Class Dual PDE3/4 Inhibitor, Demonstrates that Its Nebulized, Inhaled Formulation Is Appropriate for Delivering Optimal Pulmonary Dose
    Newman, K. B.
    Armstrong, M.
    Maurer, B. T.
    Ayrton, J.
    Causon, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [37] Pneumonia Associated With Inhaled Corticosteroid Use in Chronic Obstructive Pulmonary Disease: Another Perspective
    Scanlon, Paul D.
    MAYO CLINIC PROCEEDINGS, 2014, 89 (02) : 139 - 141
  • [38] Safety And Bronchodilator Effects Of Nebulized Rpl554, A Novel Dual Pde3/4 Inhibitor In COPD
    Cazzola, M.
    Calzetta, L.
    Segreti, A.
    Rogliani, P.
    Page, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [39] THERAPEUTIC POTENTIAL OF ANTIPLATELET AGENTS IN CHRONIC OBSTRUCTIVE PULMONARY-DISEASE
    FERRONI, P
    BASILI, S
    PULCINELLI, FM
    VIERI, M
    SIMEONI, S
    MASSAFRA, S
    CORDOVA, C
    GAZZANIGA, PP
    THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 1448 - 1448
  • [40] RPL554, an inhaled PDE3/4 inhibitor, causes profound and sustained bronchodilation in healthy volunteers and COPD patients
    Singh, Dave
    Banner, Kathy
    Newman, Kenneth
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
12345